Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01952678 · ClinicalTrials.gov registry record

Compare Rates of Agreement Between Clinical Diagnosis and Visual Assessment of DaTscan™ Images in Non-Caucasian and Caucasian Subjects With Parkinson's Disease (PD) or Essential Tremor (ET)

A clinical trial of Parkinson's Disease and Essential Tremor, sponsored by GE Healthcare.

Completed
Registry status
204
Enrollment target
1
Study location

NCT01952678 is a study of Parkinson's Disease and Essential Tremor that has completed, run by GE Healthcare. The registered enrollment target is 204 participants, below the 641-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01952678, a study of Parkinson's Disease and Essential Tremor, has completed, sponsored by GE Healthcare.

COMPLETED
Registry status
204 participants
Enrollment target
1
Study location

Study Summary

The primary objective of this study is to determine if the diagnostic performance of DaTscan™ single photon emission computed tomography (SPECT) imaging is different in non-Caucasian subjects compared with Caucasian subjects with movement disorders.

Interventions

  • OTHER DaTscan™ - Non-Caucasian Participants
  • OTHER DaTscan™ - Caucasian Participants

Study Locations (1)

Massachusetts

  • GE Healthcare - Marlborough

Trial Details

FieldValue
Enrollment Target 204 participants
Start Date 2013-07-30
Est. Completion 2016-05

Sponsor

GE Healthcare

99 total trials

What the Registry Record Tells You About NCT01952678

The ClinicalTrials.gov registry entry for NCT01952678 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 641-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (68% lower). The listed sponsor is GE Healthcare, which has 99 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which DaTscan™ - Non-Caucasian Participants is the first listed.

NCT01952678 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01952678 about?

NCT01952678 is a clinical study titled "Compare Rates of Agreement Between Clinical Diagnosis and Visual Assessment of DaTscan™ Images in Non-Caucasian and Caucasian Subjects With Parkinson's Disease (PD) or Essential Tremor (ET)". The primary objective of this study is to determine if the diagnostic performance of DaTscan™ single photon emission computed tomography (SPECT) imaging is different in non-Caucasian subjects compared with Caucasian subjects with movement disorders.

What is the current status of trial NCT01952678?

This trial is currently completed. The enrollment target is 204 participants. The study started on 2013-07-30. Estimated completion is 2016-05.

What conditions does trial NCT01952678 study?

This clinical trial studies the following conditions: Parkinson's Disease, Essential Tremor.

What interventions are being tested in trial NCT01952678?

The interventions under investigation include: DaTscan™ - Non-Caucasian Participants (OTHER), DaTscan™ - Caucasian Participants (OTHER).

Who is sponsoring clinical trial NCT01952678?

This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01952678 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.